What side effects does Benlysta (belimumab) commonly cause?
Benlysta can cause side effects that range from mild reactions to more serious problems. Commonly reported side effects include nausea and infections, such as upper respiratory tract infections. Patients can also experience infusion-related symptoms when the drug is given intravenously (IV), including reactions during or shortly after the infusion.
What infusion-related reactions should patients watch for?
For people receiving Benlysta by IV infusion, infusion-related reactions are a key concern. These can include symptoms such as headache, dizziness, rash, nausea, and trouble breathing during the infusion or shortly afterward. If symptoms occur during an infusion, clinicians typically pause or slow the infusion and treat the reaction as needed.
What serious side effects are possible?
More serious risks include infections that can become severe, since Benlysta affects the immune system. Patients should seek urgent medical care if they develop signs of infection (for example, fever, worsening cough, or other symptoms that do not improve). Other serious hypersensitivity-type reactions can also occur, requiring immediate medical attention.
What infection risks should patients and caregivers know?
Because Benlysta alters parts of immune activity, it may increase the risk of infections. The risk and severity depend on factors like other immune-modifying medications being used and overall health. Clinicians generally monitor closely for infections and may delay dosing if a significant infection develops.
Are side effects different between the IV and the self-injection forms?
Some side effects are tied to how the medication is given. Infusion-related reactions are mainly relevant to the IV form. With self-injection (subcutaneous) dosing, local injection-site reactions can occur (for example, redness or discomfort where the medication is injected), while systemic effects like nausea or infection risk can still happen with either route.
Who is more likely to run into problems, and when should dosing be stopped?
Patients who already have frequent or severe infections, or who take other immunosuppressive therapies, may face higher infection risk. Dosing decisions are individualized, but clinicians usually advise stopping or delaying treatment and seeking medical evaluation if a serious allergic reaction or a significant infection occurs.
What should you report to your doctor right away?
Contact a healthcare professional urgently for symptoms that suggest:
- a serious allergic or infusion reaction (especially with IV dosing)
- a significant infection (fever, severe or worsening symptoms)
- symptoms that could indicate a worsening overall condition
Sources
- [1] https://www.drugs.com/benlysta.html